| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. |
in this study, we compared ans activity between oral aripiprazole and aripiprazole once-monthly (aom) in schizophrenia. |
2023-03-03 |
2023-08-14 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. |
the effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from us claims data. |
2023-02-13 |
2023-08-14 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. |
to evaluate the impact of timing of aripiprazole once-monthly (aom) initiation on healthcare resource utilization (hcru), risk of hospitalization, and healthcare costs in patients with schizophrenia. |
2023-02-13 |
2023-08-14 |
Not clear |
| Chittaranjan Andrad. Prolactin-Raising and Prolactin-Sparing Antipsychotic Drugs and the Risk of Fracture and Fragility Fracture in Patients With Schizophrenia, Dementia, and Other Disorders. The Journal of clinical psychiatry. vol 84. issue 1. 2023-02-01. PMID:36724110. |
an observational study that controlled for confounding by indication and illness severity found that fragility fractures in patients with schizophrenia were associated with higher daily doses, higher cumulative doses, longer duration of treatment, and prolactin-raising rather than prolactin-sparing antipsychotics; in patients receiving prolactin-raising antipsychotics, the concurrent use of aripiprazole appeared protective. |
2023-02-01 |
2023-08-14 |
Not clear |
| Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research. vol 252. 2023-01-27. PMID:36706475. |
to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. |
2023-01-27 |
2023-08-14 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 1. 2023-01-26. PMID:36700312. |
effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. |
2023-01-26 |
2023-08-14 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 1. 2023-01-26. PMID:36700312. |
this study investigated the effectiveness of switching to once-monthly long-acting injectable (lai) aripiprazole from other second-generation antipsychotics including lai paliperidone palmitate in both recent-onset and chronic schizophrenia patients. |
2023-01-26 |
2023-08-14 |
Not clear |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences. 2023-01-17. PMID:36649751. |
sonic hedgehog pathway as a new target of atypical antipsychotics: revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. |
2023-01-17 |
2023-08-14 |
rat |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences. 2023-01-17. PMID:36649751. |
in this study, effects of the anti-psychotics amisulpride and/or aripiprazole on the shh-pathway and its relation to cognitive functions and neurogenesis in a rat model of schizophrenia were tested. |
2023-01-17 |
2023-08-14 |
rat |
| Alessandro Cuomo, Eugenio Aguglia, Stefano Biagini, Alessandro Carano, Massimo Clerici, Armando D'Agostino, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Claudia Libri, Francesco Lombardi, Matteo Lupi, Giuseppe Maina, Giovanni Martinotti, Pietro Nigro, Mauro Pettorruso, Valerio Ricci, Eros Rossi, Felicia Russo, Andrea Fagiolin. Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 43. issue 1. 2022-12-30. PMID:36584247. |
two-injection start regimen of long-acting aripiprazole in 133 patients with schizophrenia. |
2022-12-30 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
[modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. |
2022-12-20 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
according to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia. |
2022-12-20 |
2023-08-14 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN. 2022-12-20. PMID:36539584. |
effects of glycogen synthase kinase-3 beta gene polymorphisms on the plasma concentration of aripiprazole in chinese patients with schizophrenia: a preliminary study. |
2022-12-20 |
2023-08-14 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN. 2022-12-20. PMID:36539584. |
this study explored the differences in glycogen synthase kinase-3 beta (gsk3β) gene polymorphisms between patients with schizophrenia and healthy controls and investigated the association between gene polymorphisms and plasma concentration of aripiprazole. |
2022-12-20 |
2023-08-14 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry. vol 22. issue 1. 2022-12-09. PMID:36482352. |
treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the reliam study. |
2022-12-09 |
2023-08-14 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry. vol 22. issue 1. 2022-12-09. PMID:36482352. |
reliam, real-life assessment of abilify maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (aom) under real-life conditions. |
2022-12-09 |
2023-08-14 |
Not clear |
| Karl Josef Föhr, Michael Rapp, Michael Fauler, Thomas Zimmer, Bettina Jungwirth, David Alexander Christian Messere. Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. International journal of molecular sciences. vol 23. issue 21. 2022-11-11. PMID:36361681. |
aripiprazole is an atypical antipsychotic drug, which is prescribed for many psychiatric diseases such as schizophrenia and mania in bipolar disorder. |
2022-11-11 |
2023-08-14 |
Not clear |
| Lin-Fei Chen, Ying Chen, You-Yu Duan, Man-Man Zhang, Pei-Yao Xu, Ranjith Kumar Kankala, Shi-Bin Wang, Ai-Zheng Che. Preparation of aripiprazole-poly(methyl vinyl ether- Regenerative biomaterials. vol 9. 2022-11-04. PMID:36330352. |
preparation of aripiprazole-poly(methyl vinyl ether- aripiprazole (ari), a second-generation atypical antipsychotic drug approved for schizophrenia treatment, shows good efficacy against depression. |
2022-11-04 |
2023-08-14 |
Not clear |
| Yasemin Eldemir Okay, İbrahim Halil Kenger, Hamit Yildiz, Mehmet Tahir Hüsunet, Lale Dönbak, Ahmet Kayraldi. Drug and chemical toxicology. 2022-10-24. PMID:36278274. |
in line with these results, it was observed that the use of aripiprazole in the treatment of schizophrenia did not pose any acute genotoxic and cytotoxic risk. |
2022-10-24 |
2023-08-14 |
human |
| Xenia M Hart, Christoph Hiemke, Luzie Eichentopf, Xenija M Lense, Hans Willi Clement, Andreas Conca, Frank Faltraco, Vincenzo Florio, Jessica Grüner, Ursula Havemann-Reinecke, Espen Molden, Michael Paulzen, Georgios Schoretsanitis, Thomas G Riemer, Gerhard Gründe. Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology. 2022-10-04. PMID:36195732. |
therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis. |
2022-10-04 |
2023-08-14 |
Not clear |